Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors

Science Signaling

Volumn 8, Issue 403, 2015, Pages

  Hsieh, Andrew C ^a,c,d   Nguyen, Hao G ^a   Wen, Lexiaochuan ^a   Edlind, Merritt P ^a   Carroll, Peter R ^a   Kim, Won ^a   Ruggero, Davide ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUPARLISIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INITIATION FACTOR 4A; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SAPANISERTIB; TELOMERASE REVERSE TRANSCRIPTASE; EIF4EBP1 PROTEIN, HUMAN; ENZYME INHIBITOR; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLS BY BODY ANATOMY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN SYNTHESIS; RNA TRANSLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; EPITHELIUM CELL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPITHELIAL CELLS; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TOR SERINE-THREONINE KINASES;

EID: 84947811131     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aad5111     Document Type: Article

References (38)

1. B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers, W. L. Gerald, Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
2. N. Choi, B. Zhang, L. Zhang, M. Ittmann, L. Xin, Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 21, 253-265 (2012).
3. T. Stoyanova, A. R. Cooper, J. M. Drake, X. Liu, A. J. Armstrong, K. J. Pienta, H. Zhang, D. B. Kohn, J. Huang, O. N. Witte, A. S. Goldstein, Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc. Natl. Acad. Sci. U.S.A. 110, 20111-20116 (2013).
4. X. Wang, M. Kruithof-deJulio, K. D. Economides, D. Walker, H. Yu, M. V. Halili, Y.-P. Hu, S. M. Price, C. Abate-Shen, M. M. Shen, A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500 (2009).
5. A.-C. Gingras, B. Raught, S. P. Gygi, A. Niedzwiecka, M. Miron, S. K. Burley, R. D. Polakiewicz, A. Wyslouch-Cieszynska, R. Aebersold, N. Sonenberg, Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864 (2001).
6. A.-C. Gingras, S. G. Kennedy, M. A. O'Leary, N. Sonenberg, N. Hay, 4E-BP1, A repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502-513 (1998).
7. A. C.Hsieh, Y. Liu, M.P. Edlind, N. T. Ingolia, M. R. Janes, A.Sher, E. Y. Shi, C. R. Stumpf, C. Christensen, M. J. Bonham, S. Wang, P. Ren, M. Martin, K. Jessen, M. E. Feldman, J. S. Weissman, K. M. Shokat, C. Rommel, D. Ruggero, The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55-61 (2012).
8. D. Ruggero, L. Montanaro, L. Ma, W. Xu, P. Londei, C. Cordon-Cardo, P. P. Pandolfi, The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10, 484-486 (2004).
9. A. Lazaris-Karatzas, K. S. Montine, N. Sonenberg, Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345, 544-547 (1990).
10. A. Haghighat, N. Sonenberg, eIF4G dramatically enhances the binding of eIF4E to the mRNA 5′-cap structure. J. Biol. Chem. 272, 21677-21680 (1997).
11. G. W. Rogers Jr., N. J. Richter, W. C. Merrick, Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A. J. Biol. Chem. 274, 12236-12244 (1999).
12. A. Pause, G. J. Belsham, A.-C. Gingras, O. Donzé, T.-A. Lin, J. C. Lawrence Jr., N. Sonenberg, Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371, 762-767 (1994).
13. M. P. Edlind, A. C. Hsieh, PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J. Androl. 16, 378-386 (2014).
14. S. Wang, J. Gao, Q. Lei, N. Rozengurt, C. Pritchard, J. Jiao, G. V. Thomas, G. Li, P. Roy-Burman, P. S. Nelson, X. Liu, H. Wu, Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
15. A. C. Hsieh, M. Costa, O. Zollo, C. Davis, M. E. Feldman, J. R. Testa, O. Meyuhas, K. M. Shokat, D. Ruggero, Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249-261 (2010).
16. D. Lawson, Y. Zong, S. Memarzadeh, L. Xin, J. Huang, O. Witte, Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl. Acad. Sci. U.S.A. 107, 2610-2615 (2010).
17. I. Ruvinsky, N. Sharon, T. Lerer, H. Cohen, M. Stolovich-Rain, T. Nir, Y. Dor, P. Zisman, O. Meyuhas, Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19, 2199-2211 (2005).
18. J. R. Graff, B. W. Konicek, R. L. Lynch, C. A. Dumstorf, M. S. Dowless, A. M. McNulty, S. H. Parsons, L. H. Brail, B.M. Colligan, J. W. Koop, B.M. Hurst, J. A. Deddens, B. L. Neubauer, L. F. Stancato, H. W. Carter, L. E. Douglass, J. H. Carter, eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69, 3866-3873 (2009).
19. C. Andrieu, D. Taieb, V. Baylot, S. Ettinger, P. Soubeyran, A. De-Thonel, C. Nelson, C. Garrido, A. So, L. Fazli, F. Bladou, M. Gleave, J. L. Iovanna, P. Rocchi, Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 29, 1883-1896 (2010).
20. S. A. F. Morad, M. Schmid, B. Büchele, H.-U. Siehl, M. El Gafaary, O. Lunov, T. Syrovets, T. Simmet, A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells. Mol. Pharmacol. 83, 531-541 (2013).
21. X. Wu, J. Wu, J. Huang, W. C. Powell, J. F. Zhang, R. J. Matusik, F. O. Sangiorgi, R. E. Maxson, H. M. Sucov, P. Roy-Burman, Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61-69 (2001).
22. G. Belteki, J. Haigh, N. Kabacs, K. Haigh, K. Sison, F. Costantini, J.Whitsett, S. E. Quaggin, A. Nagy, Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Res. 33, e51 (2005).
23. O. Pinter, Z. Beda, Z. Casaba, I. Gerendai, Differences in the onset of puberty in selected inbred mouse strains. Endocrine Abstracts 14, 617 (2007).
24. L. Furic, L. Rong, O. Larsson, I. H. Koumakpayi, K. Yoshida, A. Brueschke, E. Petroulakis, N. Robichaud, M. Pollak, L. A. Gaboury, P. P. Pandolfi, F. Saad, N. Sonenberg, eIF4E Phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. U.S.A. 107, 14134-14139 (2010).
25. R. Berger, P. G. Febbo, P. K. Majumder, J. J. Zhao, S. Mukherjee, S. Signoretti, K. T. Campbell, W. R. Sellers, T. M. Roberts, M. Loda, T. R. Golub, W. C. Hahn, Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 64, 8867-8875 (2004).
26. R. Azar, A. Alard, C. Susini, C. Bousquet, S. Pyronnet, 4E-BP1 is a target of Smad4 essential for TGFβ-mediated inhibition of cell proliferation. EMBO J. 28, 3514-3522 (2009).
27. R. Azar, C. Lasfargues, C. Bousquet, S. Pyronnet, Contribution of HIF-1a in 4E-BP1 gene expression. Molec. Cancer Res. 11, 54-61 (2013).
28. E. R. Zunder, Z. A. Knight, B. T. Houseman, B. Apsel, K. M. Shokat, Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α. Cancer Cell 14, 180-192 (2008).
29. B. S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty, V. K. Arora, C. Le, J. Koutcher, H. Scher, P. T. Scardino, N. Rosen, C. L. Sawyers, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTENdeficient prostate cancer. Cancer Cell 19, 575-586 (2011).
30. D. J. Mulholland, L. M. Tran, Y. Li, H. Cai, A. Morim, S. Wang, S. Plaisier, I. P. Garraway, J. Huang, T. G. Graeber, H. Wu, Cell autonomous role of PTEN in regulating castrationresistant prostate cancer growth. Cancer Cell 19, 792-804 (2011).
31. T. Muranen, L. M. Selfors, D. T. Worster, M. P. Iwanicki, L. Song, F. C. Morales, S. Gao, G. B. Mills, J. S. Brugge, Inhibition of PI3K/mTOR leads to adaptive resistance in matrixattached cancer cells. Cancer Cell 21, 227-239 (2012).
32. I. B. Weinstein, Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 297, 63-64 (2002).
33. L. Boussemart, H. Malka-Mahieu, I. Girault, D. Allard, O. Hemmingsson, G. Tomasic, M. Thomas, C. Basmadjian, N. Ribeiro, F. Thuaud, C. Mateus, E. Routier, N. Kamsu-Kom, S. Agoussi, A. M. Eggermont, L. Désaubry, C. Robert, S. Vagner, EIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105-109 (2014).
34. S. Mallya, B. A. Fitch, J. S. Lee, L. So, M. R. Janes, D. A. Fruman, Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLOS One 9, e88865 (2014).
35. C. L. Cope, R. Gilley, K. Balmanno, M. J. Sale, K. D. Howarth, M. Hampson, P. D. Smith, S. M. Guichard, S. J. Cook, Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J. Cell Sci. 127, 788-800 (2014).
36. T. Alain, M. Morita, B. D. Fonseca, A. Yanagiya, N. Siddiqui, M. Bhat, D. Zammit, V. Marcus, P. Metrakos, L.-A. Voyer, V. Gandin, Y. Liu, I. Topisirovic, N. Sonenberg, eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 72, 6468-6476 (2012).
37. N. Ilic, T. Utermark, H. R. Widlund, T. M. Roberts, PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. U.S.A. 108, E699-E708 (2011).
38. J. C. Bendell, J. Rodon, H. A. Burris, M. de Jonge, J. Verweij, D. Birle, D. Demanse, S. S. De Buck, Q. C. Ru, M. Peters, M. Goldbrunner, J. Baselga, Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290 (2012).